GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HeXun Biosciences Co 6986.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

39.00

-2.74%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 293.2m

FY2021FY2025

Net income

TWD 111.9m

FY2021FY2025

Free cash flow

TWD 135.0m

FY2021FY2025

Shareholders' equity

TWD 741.6m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueTWD 293.2mTWD 286.4mTWD 130.6mTWD 49.5m—
Gross profitTWD 266.3mTWD 260.7mTWD 113.7mTWD 44.6m—
Research and developmentTWD 99.2mTWD 65.4mTWD 53.2mTWD 39.4mTWD 44.7m
Operating incomeTWD 118.0mTWD 155.7mTWD 27.4m−TWD 4.0m−TWD 50.7m
Net incomeTWD 111.9mTWD 147.2mTWD 33.5m−TWD 5.2m−TWD 43.0m
Diluted earnings per share2.393.200.73-0.11-0.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsTWD 837.1mTWD 706.9mTWD 571.4mTWD 404.2mTWD 294.6m
Cash and short-term investments—TWD 373.0mTWD 329.7mTWD 191.7mTWD 85.0m
Total liabilitiesTWD 95.5mTWD 86.3mTWD 98.1mTWD 89.3mTWD 79.9m
Debt—TWD 35.0mTWD 70.1mTWD 69.4mTWD 74.1m
Shareholders' equityTWD 741.6mTWD 620.6mTWD 473.4mTWD 314.9mTWD 214.8m
Shares outstanding47m46m46m47m47m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsTWD 163.9mTWD 120.9mTWD 43.1mTWD 11.2m−TWD 35.5m
Capital spending−TWD 28.9m−TWD 37.3m−TWD 22.8m−TWD 1.2m—
Free cash flowTWD 135.0mTWD 83.6mTWD 20.3mTWD 10.0m−TWD 35.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 93.9mTWD 72.5mTWD 85.3mTWD 56.6mTWD 75.7mTWD 75.7mTWD 153.0mTWD 76.5m
Gross profitTWD 90.0mTWD 64.7mTWD 77.0mTWD 48.7mTWD 70.3mTWD 70.3mTWD 128.1mTWD 68.5m
Operating incomeTWD 51.1mTWD 31.5mTWD 35.8mTWD 12.2mTWD 35.0mTWD 35.0mTWD 82.8mTWD 41.4m
Net incomeTWD 38.4mTWD 27.4mTWD 37.0mTWD 13.6mTWD 30.7mTWD 30.7mTWD 70.0mTWD 35.0m
Diluted earnings per share0.820.590.790.290.660.661.520.76
Cash from operationsTWD 39.0mTWD 27.0mTWD 23.0mTWD 73.0mTWD 67.0mTWD 33.0mTWD 108.0mTWD 54.0m
Capital spending−TWD 5.0m−TWD 8.0m−TWD 8.0m−TWD 8.0m−TWD 5.0m−TWD 5.0m−TWD 11.0m−TWD 5.0m
Free cash flowTWD 34.0mTWD 19.0mTWD 15.0mTWD 65.0mTWD 62.0mTWD 28.0mTWD 97.0mTWD 49.0m
Total assetsTWD 1.18bnTWD 851.1mTWD 837.1mTWD 792.8mTWD 785.0mTWD 785.0mTWD 706.9mTWD 706.9m
Cash and short-term investments———TWD 496.0mTWD 429.7mTWD 429.7mTWD 373.0mTWD 373.0m
Debt———TWD 3.9mTWD 3.5mTWD 3.5mTWD 6.1mTWD 3.0m
Shareholders' equityTWD 1.07bnTWD 770.3mTWD 741.6mTWD 703.8mTWD 686.0mTWD 686.0mTWD 620.6mTWD 620.6m

Financial ratios

Data as of 26 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin90.8%91.0%87.1%90.2%——
Operating margin43.3%56.8%27.1%-7.2%——
Net margin38.2%51.4%25.6%-10.5%——
Return on equity15.1%23.7%7.1%-1.6%-20.0%—
Return on assets13.4%20.8%5.9%-1.3%-14.6%—
Free cash flow yield9.4%7.8%3.3%———
Revenue growth2.4%119.4%163.9%———
Earnings growth-24.0%339.6%-745.5%-87.9%——
Current ratio9.75x8.99x12.05x10.55x11.94x6.67x
Debt to equity—0.00x0.08x0.13x0.20x0.04x
Equity ratio88.6%87.8%82.8%77.9%72.9%67.5%
Interest coverage114.04x138.42x19.06x-2.17x-26.31x—
R&D as a share of sales33.8%22.8%40.8%79.6%——
Buybacks as a share of market value-1.6%-0.2%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue81.0%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin90.9%90.2%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings26.321.189.0
Price to sales10.110.922.8

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.